

IN THE CLAIMS:

Please amend Claims 33, 34, 54, 73, 75 and 79 as follows in re-written "clean format".

33. (Twice Amended/Clean) An antisense oligonucleotide, wherein the antisense oligonucleotide inhibits the expression of a nucleic acid molecule encoding a human EDG-1 receptor and wherein the antisense oligonucleotide includes the translational initiation site of the nucleic acid molecule encoding the human EDG-1 receptor.

34. (Amended/Clean) The antisense oligonucleotide of claim 33 wherein the antisense oligonucleotide hybridizes to the nucleic acid molecule encoding the EDG-1 receptor.

54. (Thrice Amended/Clean) An antisense oligonucleotide, wherein the antisense oligonucleotide inhibits the expression of a nucleic acid molecule encoding a human EDG-3 receptor and wherein the antisense oligonucleotide includes the translational initiation site of the nucleic acid molecule encoding the human EDG-3 receptor.

73. (Twice Amended/Clean) An antisense oligonucleotide, wherein the antisense oligonucleotide inhibits the expression of a nucleic acid molecule encoding a human EDG-1 or EDG-3 receptor and wherein the antisense oligonucleotide includes the translational initiation site of the nucleic acid molecule encoding the human EDG-1 or EDG-3 receptor.

75. (Twice Amended/Clean) The antisense oligonucleotide of claim 73 comprising SEQ ID NO:5.

79. (Amended/Clean) A method of affecting intracellular signaling between cells, comprising contacting the cells with an antisense oligonucleotide in an amount effective to inhibit the expression of a nucleic acid molecule encoding the human EDG-1 or EDG-3 receptor.